Featured
Scam headhunters targeting Aussie pharma execs
Scammers impersonating legitimate Big Pharma in-house recruiters are targeting Australian industry professionals with lucrative high-income roles as part of a money-making racket
Sales, Marketing & Public Relations
New access model reshaping pharma
Direct-to-patient programs are considered "mission critical" according to a third of pharma professionals who believe it will transform access
Pipeline & Intellectual Property
Supply setback extends shortage into 2027
A national shortage of this treatment is expected to continue into 2027 after the pharma confirmed an order, expected this month, is now “unlikely”
Patients
Riders pedal past fundraising target
Aussie BMS staffers have raised double their original goal for Rare Cancers Australia through an 18,000 kilometre, 15-day cycling event in Japan
Featured
Was this Aussie pharma's Best Kept Secret?
A bombshell announcement from two industry high-flyers was kept completely under wraps despite multiple big-name organisations getting on board with the new pharma venture. And now, they've detailed a potentially market-disrupting business model for medicines access
Featured
Pharma sold at undisclosed price
An international private equity firm has reached an agreement to acquire this pharma, with plans to support its global growth ambitions
Featured
Matt Zeller launches new Australian pharma
Five months after leaving Arrotex, the former Novartis Country President ANZ is launching his own Sydney-headquartered pharma company with another high-profile exec as Co-Founder
Industry & Companies
Roche unveils new tech for high-throughput genomics
The Swiss pharma is gathering experts to push its entrant into the booming next-generation sequencing market
Regulatory & Reimbursement
New drugs flood the ARTG
Last week saw a string of medicines registered on the ARTG, including two heart drugs, a new contraceptive option, and Novo’s hyped obesity pill
Government & Policy
Boosting PBS spending a political no-brainer
New research commissioned by Pfizer Australia exposes near-universal public support for expanding the PBS among Coalition, Labor, Greens and One Nation voters
Leadership & People
Country boss adds new leadership hat
AstraZeneca leader joins board to promote trade between Europe and Australia bolstering collaboration, innovation and investment
Regulatory & Reimbursement
Drugs dropped from PBAC meeting
Three drugs were removed and another added in a last-minute revision to the agenda for the PBAC's last three-day meeting for 2026
Industry & Companies
Pharma sells off Aussie business
This company will now be a specialty pharma focused on the United States with its Australian assets moving to new hands for $55M
Featured
Pfizer names permanent ANZ leader
He knows plenty about the role, having served as interim Managing Director for six months, now this leader has officially landed the top job, providing certainty for the pharma as it navigates a changing reimbursement landscape
Featured
What doctors really want Reps to talk about
More than four in 10 clinicians say conversations with reps are mostly about products but what they'd really like to discuss is this...
Jobs
Pipeline & Intellectual Property
Pharma signs its biggest ever milestones deal
Mega license agreement inked with Chinese powerhouse covering six antibody-drug conjugate and T-cell engager programs
Patients
Omico names genomic profiling partners
Four organisations have been selected to provide comprehensive genomic profiling for 25,000 Australians in the next phase of this screening program
Regulatory & Reimbursement
What drugs are on MS patients' Wish List?
While RRMS is a PBS success story with Australians having the best access to meds in the world, there are new drugs coming that also need to be funded
Regulatory & Reimbursement
11 drugs join TGA review list
An update to the TGA's prescription medicines under evaluation list shows 11 drug applications were accepted in August, signalling what could enter the Australian market next year
Pipeline & Intellectual Property
Drug fails four months after $2.2B upfront buy
Potential first-in-class treatment for a disease with high unmet need falls at the finish line of a pivotal trial after this pharma paid a hefty price in July
Pipeline & Intellectual Property
Can pharma sustain the blockbuster boom?
The number of blockbuster drugs have skyrocketed, with a new report taking a deep dive into whether industry can sustain the boom in the face of looming patent cliffs
Government & Policy
Blue wave to break against MFN
The MFN isn't going anywhere soon, and the Commonwealth will need to adjust its pricing expectations if it wants Australians to gain access to the latest medicines
Featured
One webpage, 11 Code Breaches
The hardline UK industry watchdog is at it again, slapping a company with 11 breaches of the Code over a single webpage on a Congress website after a complaint from an ex-employee which described the company's missteps as an embarrassment to the industry
Featured
Aussies tapped for regional roles
In the latest round of job moves, industry leaders move up alongside long-timers changing companies - one after almost 30 years working at the same pharma
Regulatory & Reimbursement
Pharmac says no to weight loss funding
The decision came despite a high-priority recommendation from its Advisory Group with the current fiscal environment and constraints of the public health system to blame
Regulatory & Reimbursement
Aussie race to market kicks off for obesity pills
The first oral GLP-1 drug has been approved for use in Australia for weight loss and will likely hit the private market this year, with a rival hot on its heels
Industry & Companies
Who's opening its doors in the US?
Just months after undergoing a major rebrand, this Australian biotech is embarking on its next phase of growth, with plans to establish a US subsidiary
- Industry & Companies AZ shuffles jobs to prep huge pipeline
- Awards Meet the Best Drugs of 2026
- Regulatory & Reimbursement Aussie study applauds new-gen Novartis drug
- Leadership & People Ex-Novartis GM snapped up for global role
- Pipeline & Intellectual Property Qld radiopharma defends manufacturing process
- Pipeline & Intellectual Property Aussies find new combo to tackle deadly cancer
- Regulation & Legal Federal Court slaps company with $6.5M fine
- Government & Policy AbbVie pitches a world-class PBS
- Regulatory & Reimbursement Aussies continue FDA winning streak
- Regulatory & Reimbursement Three pharmas hit with first rival